Aktuellt
SENASTE
Vitrolife provides an update ahead of the total Q4 due on 2 February. The last quarter in 2024 seems to be a mix of ongoing headwinds in parts of the Genetic Services business, mainly the US market, plus a seasonally strong technology business and decent consumable support. Vitrolife enters 2024 with a goodwill review related to acquiring Igenomix of SEK 4.3bn, or approximately 31% of the related goodwill. This is understandable considering several quarters of significant US headwinds, especially ERA testing, the fact that Igenomix was acquired during relatively high general valuations, and the increased interest rate environment that followed.
LÄS MER
